AbbVie Inc. 8K

AbbVie reported strong Q2 2026 financial results and narrowed full-year guidance while announcing a $10.9 billion acquisition of Apogee Therapeutics and highlighting multiple key regulatory approvals across its portfolio.

On July 31, 2026, AbbVie Inc. reported strong second-quarter 2026 financial results, with GAAP diluted EPS of $2.03 (up 290.4%) and adjusted diluted EPS of $3.65 (up 22.9%), on net revenues of $16.99 billion, driven by double-digit growth in its immunology and neuroscience portfolios led by Skyrizi and Rinvoq, partially offset by continued Humira erosion and modest oncology and aesthetics trends. The company highlighted portfolio revenues by segment, disclosed GAAP and non-GAAP margin metrics, and noted that results included a $0.17 per-share unfavorable impact from acquired IPR&D and milestones. AbbVie also announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion in equity value, adding late-stage immunology assets such as zumilokibart (APG777) and APG273 and prompting an update to full-year 2026 adjusted EPS guidance to a range of $13.87–$14.07, which now incorporates $0.14 per share of anticipated dilution from the proposed acquisition, partly offset by operational overperformance. The filing further detailed multiple recent regulatory approvals and label expansions across key products (Skyrizi, Rinvoq, Aquipta, Decnupaz, Venclyxto/Venclexta, Tepkinly/Epkinly, Maviret, Skinvive by Juvederm, and Boey), underscoring continued pipeline advancement in immunology, neuroscience, oncology, virology, and aesthetics, and provided reconciliations between GAAP and non-GAAP results along with updated tax rate and margin information.

Filing Facts

CIK

1551152

Ticker

ABBV

Form

8K

Source Type

fda

Accession

0001551152-26-000023

Alert Tier

8